News
31 March 2020

EIB finances AM-Pharma's development of acute kidney injury treatment

In:
Infrastructure
Region:
Europe

The EIB and Utrecht-based AM-Pharma have signed a €24 million financing agreement. The funds will be used to accelerate the development of the clinical stage biopharmaceutical company’s recombinant alkaline phosphatase enzyme, which is used to treat acute kidney injury (AKI). The...

Exclusive subscriber content…

If you are a TXF subscriber, please login to continue reading

Login

Not yet a subscriber? Join us today to continue accessing content without any restrictions

View our subscription options

Or to request access to TXF Intelligence contact us

Request Access

You might also like


Perspective
12 September 2025

Satellite finance heads back into orbit

Changing business models and technologies have made it harder for ECAs and commercial banks to support satellite launches. But the demand for satellite connectivity is strong,...

Perspective
18 September 2025

H1 2025 commodity finance data: Key takeaways

TXF's commodities data suggests that 2025 is expected to see modest growth with bigger deals going to top borrowers, ongoing regional shifts, and continued trader dominance,...